

**OXIDATION PRODUCTS OF STRICTOSAMIDE BY
IODOSOBENZENE DIACETATE**

Hideyuki Shigemori, Toshinori Kagata, and Jun'ichi Kobayashi*

*Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo
060-0812, Japan*


Abstract - Oxidation of strictosamide (**1**), a representative monoterpene indole alkaloid, by iodosobenzene diacetate (IBD) gave compounds (**2** ~ **6**), among them the structure of **3** corresponded to an oxindole derived through oxidative cleavage between C-2 and C-3 of **1**. A plausible mechanism of formation of **2** ~ **6** from strictosamide (**1**) by IBD oxidation is proposed.

Naturally occurring oxindole alkaloids have been found to possess interesting biological activity.¹ Some oxindole alkaloids, such as 3-oxo-7-hydroxy-3,7-secorhynchophylline,² Us-7, and Us-8,³ may be biosynthetically generated through oxidation from a representative monoterpene indole alkaloid, strictosidine, which is a precursor of strictosamide (**1**)⁴ isolated from plants of genera *Rhazya* (Apocynaceae), *Nauclea* (Rubiaceae), and *Uncaria* (Rubiaceae). Therefore, we examined oxidation reaction of strictosamide (**1**) from which oxindole alkaloids could be generated. In this paper we describe oxidation reaction of strictosamide (**1**) by iodosobenzene diacetate (IBD) and propose a plausible mechanism of formation of oxidation products (**2** ~ **6**) from **1**.

Treatment of strictosamide (**1**) with IBD (1 eq.) in MeOH at room temperature for 2 days yielded compounds (**2**) (20%), (**3**) (5%), (**4**) (11%), (**5**) (20%), and (**6**) (21%) (Scheme 1). The structures of **2** ~ **6** were elucidated by spectral data including MS and 2D NMR spectrometries as follows.

Compound (**2**) was shown to have the molecular formula, C₂₇H₃₂N₂O₉, by HRFABMS [*m/z* 529.2194 (M+H)⁺, Δ +0.8 mmu]. The ¹H and ¹³C NMR spectra of **2** revealed the presence of a methoxy group (δ_H 2.88; δ_C 53.3) and an imine (δ_C 182.8) from comparison with those of strictosamide (**1**). The presence of the imine at C-2 was deduced from HMBC correlations of H-6a and H-14b to the imino carbon. HMBC correlations of the methoxy protons, H-5a, H-6a, and H-9 to C-7 (δ_C 88.9) indicated that the methoxy group was attached to C-7, while a NOESY correlation between MeO-7 and H-3 suggested that the methoxy group was α-oriented.

Dedicated to the celebration of the 75th birthday of Professor Yuichi Kanaoka



Scheme 1

The molecular formula, $C_{27}H_{32}N_2O_{11}$, of compound (**3**) was established by HRFABMS spectrum [m/z 561.2050 ($M+H$)⁺, Δ -3.4 mmu]. The 1H - 1H COSY spectrum revealed connectivities of C-5 to C-6, C-9 to C-12, C-14 to C-15, C-18 to C-21, C-15 to C-20, and C-1' to C-6'. HMBC correlations of H-9 to C-7 (δ_C 72.5) and C-13 (δ_C 144.4), H-12 to C-8 (δ_C 129.2), H₂-6 to C-2 (δ_C 180.2) and C-7, a methoxy protons (δ_H 3.02) to C-7 indicated the presence of an oxindole ring, in which a methoxy group was attached to C-7. HMBC correlations of H₂-5 to C-3 (δ_C 174.4) and C-22 (δ_C 168.6), H₂-14 to C-3, and H-17 to C-22 revealed the presence of a glutarimide moiety (C-3, C-14 - C-16, C-22, and N-4), which was connected to the dihydropyran ring. The absolute configuration at C-7 was elucidated to be *R*, since a positive Cotton curve at the region of 300-260 nm and a negative curve at the region of 260-230 nm were observed in the CD spectrum of **3**.⁵

Compound (**4**) was shown to have the molecular formula, $C_{27}H_{30}N_2O_9$, by HRFABMS spectrum [m/z 549.1868 ($M+Na$)⁺, Δ +1.9 mmu]. The 1H and ^{13}C NMR and HMQC spectra of **4** indicated the presence of one methoxy (δ_H 3.65, s; δ_C 57.0), one acetal (δ_H 5.69, s; δ_C 98.3), and one pyridone ring (δ_H 6.68, s, H-14; δ_C 140.4, C-3, 102.6, C-14, 149.8, C-15, 122.0, C-16). The presence of the pyridone ring (C-3, N-4, C-14 to C-16, and C-22) was also supported by HMBC correlations of H-14 to C-2, C-3, and C-16 and H-20 to C-15 and the UV spectrum of **4**. HMBC correlations of the methoxy protons and C-17 (δ_C 98.3), and H-17 to C-15, C-16, and C-21 indicated that the methoxy group was attached to C-17. The α -orientation of the methoxy group at C-17 was deduced from a NOESY correlation between H-17 and H-20.

The molecular formula, C₂₇H₃₂N₂O₉, of compound (**5**) was established by HRFABMS spectrum [*m/z* 529.2183 (M+H)⁺, Δ -0.3 mmu]. The ¹H and ¹³C NMR and HMQC spectra of **5** indicated the presence of one methoxy (δ_H 3.57, s; δ_C 57.5) and one oxymethine (δ_H 4.67; δ_C 74.6). HMBC correlations between the methoxy protons and C-6 (δ_C 74.6), and the oxymethine proton to C-2 (δ_C 137.9), C-5 (δ_C 46.7), and C-7 (δ_C 112.0) revealed that the methoxy group was attached to C-6, while a NOESY correlations of H-3 to H-5b (δ_H 3.02) and H-5a (δ_H 5.35) to MeO-6 indicated that the methoxy group was β-oriented.


Compound (**6**) was shown to have the molecular formula, C₂₈H₃₄N₂O₁₀, by HRFABMS [*m/z* 559.2260 (M+H)⁺, Δ -3.2 mmu]. The ¹H and ¹³C NMR and HMQC spectra of **6** indicated the presence of two methoxy groups (δ_H 3.03, s; δ_C 55.0 and δ_H 3.40, s; δ_C 53.2) and one imine (δ_C 180.7). The presence of the imine at C-2 was deduced from an HMBC correlation of H-6a to the imino carbon. HMBC correlations of the methoxy protons (δ_H 3.03), H-5a, H-6a, and H-9 to C-7 (δ_C 88.9) and the methoxy protons (δ_H 3.40), H-14a, and H-15 to C-3 (δ_C 90.4) indicated that the two methoxy groups were attached to C-7 and C-3, while NOESY correlations of MeO-3 to H-15 and MeO-7 revealed that both methoxy groups were β-oriented.

A plausible mechanism of formation of compounds (**2** ~ **6**) from strictosamide (**1**) by IBD oxidation in MeOH is proposed as shown in Scheme 2. In the first step IBD induces the oxidation of C-3 (pathway **a**) or N-1 (pathway **b**) of **1**, resulting in generation of intermediates (**A**) and (**B**), respectively. Oxidation of ring D of **A** and addition of MeOH to C-17 give compound (**4**), while the dehydration at C-6 of **B** (pathway **c**) and then addition of MeOH to C-6 afford compound (**5**). On the other hand, addition of MeOH to C-7 of **B** (pathway **d**) give compound (**2**) (MeO-7 α) and the stereoisomer (**2'**) (MeO-7 β). Dehydration at C-3 of **2'** followed by addition of MeOH to C-3 yield compound (**6**). Oxidation at C-3 of **C** followed by formation of a peroxy ring at C-2 and C-3 and then cleavage of the C-2 – C-3 bond afford compound (**3**). Oxindole alkaloids with a hydroxy group at C-7 in place of the methoxy group like **3** may be obtained from plants of Apocynaceae or Rubiaceae.

EXPERIMENTAL

General Methods. ¹H and ¹³C NMR spectra were recorded on 500 and 600 MHz spectrometers. The 3.35 ppm resonance of residual CHD₂OD and 49.8 ppm of CD₃OD were used as internal references, respectively. FABMS was measured by using glycerol as a matrix.

Oxidation of Strictosamide (1**) by Iodosobenzene Diacetate (IBD):** To a solution of strictosamide (**1**, 20 mg, 40 μmol) in MeOH (1.0 mL) was added IBD (13 mg, 40 μmol). The solution was stirred at rt for 2 days, and the reaction mixture was concentrated in vacuo. The residue was applied to C₁₈ HPLC (Develosil ODS HG-5, 1.0 x 25 cm, Nomura Chemical, MeOH/H₂O, 7:3, UV detection at 254 nm) to afford compounds (**2**) (4.3 mg, *t_R* 9.6 min), (**3**) (1.2 mg, *t_R* 8.0 min), (**4**)



Scheme 2

(**2**) (2.2 mg, t_R 12.4 min), (**5**) (4.3 mg, t_R 10.8 min), and (**6**) (4.9 mg, t_R 13.6 min).

Compound (2): A colorless amorphous solid; IR (KBr) ν_{\max} 3436, 1644, and 1065 cm^{-1} ; UV (MeOH) λ_{\max} 208 (ϵ 19000) and 238 (15000) nm; ^1H NMR (CD_3OD): δ 7.65 (1H, d, $J = 7.5$ Hz, H-

12), 7.50 (1H, t, $J = 7.5$ Hz, H-11), 7.48 (1H, d, $J = 7.5$ Hz, H-9), 7.41 (1H, d, $J = 2.0$ Hz, H-17), 7.38 (1H, t, $J = 7.5$ Hz, H-10), 5.67 (1H, dt, $J = 16.8$ and 10.6 Hz, H-19), 5.39 (1H, dd, $J = 16.8$ and 1.9 Hz, H-18a), 5.37 (1H, dd, $J = 10.6$ and 1.9 Hz, H-18b), 5.50 (1H, d, $J = 1.9$ Hz, H-21), 4.80 (1H, br s, H-3), 4.68 (1H, m, H-5a), 4.68 (1H, d, $J = 8.0$ Hz, H-1'), 3.96 (1H, dd, $J = 12.5$ and 1.9 Hz, H-6'a), 3.73 (1H, m, H-6'b), 3.55 (1H, m, H-15), 3.40 (1H, m, H-3'), 3.35 (1H, m, H-5b), 3.34 (1H, m, H-5'), 3.30 (1H, m, H-4'), 3.20 (1H, m, H-2'), 2.88 (3H, s, MeO-7), 2.85 (1H, m, H-20), 2.61 (1H, dt, $J = 13.7$ and 1.9 Hz, H-6a), 2.48 (1H, dd, $J = 13.7$ and 5.0 Hz, H-14a), 2.05 (1H, td, $J = 13.7$ and 6.0 Hz, H-14b), 1.45 (1H, m, H-6b); ^{13}C NMR (CD_3OD): δ 182.8 (C-2), 166.3 (C-22), 155.8 (C-13 and C-17), 138.3 (C-8 and C-19), 131.7 (C-11), 128.9 (C-10), 125.3 (C-9), 125.1 (C-12), 121.5 (C-18), 109.5 (C-16), 101.4 (C-1'), 99.2 (C-21), 88.9 (C-7), 79.1 (C-5'), 78.9 (C-3'), 75.4 (C-2'), 72.3 (C-4'), 63.5 (C-6'), 56.3 (C-3), 53.3 (MeO-7), 44.8 (C-20), 40.6 (C-5), 40.5 (C-6), 25.6 (C-15), and 25.1 (C-14); FABMS m/z 529 ($\text{M}+\text{H}$)⁺; HRFABMS m/z 529.2194 ($\text{M}+\text{H}$)⁺, calcd for $\text{C}_{27}\text{H}_{33}\text{N}_2\text{O}_9\text{Na}$, 529.2186.

Compound (3): A colorless amorphous solid; IR (KBr) ν_{max} 3430 and 1623 cm^{-1} ; UV (MeOH) λ_{max} 208 (ϵ 29000) and 246 (17000) nm; CD (MeOH) 217 ($\Delta\epsilon$ +1.9), 245 (-5.8), 292 (+3.2), and 328 (-1.0) nm; ^1H NMR (CD_3OD): δ 7.59 (1H, d, $J = 2.3$ Hz, H-17), 7.38 (1H, d, $J = 7.5$ Hz, H-9), 7.36 (1H, t, $J = 7.5$ Hz, H-11), 7.16 (1H, t, $J = 7.5$ Hz, H-10), 6.95 (1H, d, $J = 7.5$ Hz, H-12), 5.61 (1H, d, $J = 1.3$ Hz, H-21), 5.58 (1H, m, H-19), 5.36 (1H, dd, $J = 15.2$ and 1.5 Hz, H-18a), 5.27 (1H, dd, $J = 12.0$ and 1.5 Hz, H-18b), 4.71 (1H, d, $J = 8.1$ Hz, H-1'), 3.95 (1H, m, H-5a), 3.92 (1H, m, H-6'a), 3.78 (1H, m, H-5b), 3.68 (1H, m, H-6'b), 3.40 (1H, m, H-3'), 3.37 (1H, m, H-5'), 3.32 (1H, m, H-4'), 3.24 (1H, m, H-15), 3.21 (1H, m, H-2'), 3.02 (3H, s, MeO-7), 2.72 (1H, m, H-20), 2.48 (1H, dd, $J = 16.2$ and 5.6 Hz, H-14a), 2.28 (1H, dd, $J = 16.2$ and 15.0 Hz, H-14b), and 2.20 (2H, m, H-6); ^{13}C NMR (CD_3OD): δ 180.2 (C-2), 174.4 (C-3), 168.6 (C-22), 153.2 (C-17), 144.4 (C-13), 133.9 (C-19), 131.8 (C-11), 129.2 (C-8), 126.5 (C-9), 124.8 (C-10), 122.1 (C-18), 112.3 (C-12), 109.6 (C-16), 100.4 (C-1'), 98.4 (C-21), 78.9 (C-5'), 78.6 (C-3'), 75.3 (C-2'), 72.5 (C-7), 72.0 (C-4'), 63.3 (C-6'), 53.6 (MeO-7), 44.3 (C-20), 36.3 (C-6), 36.0 (C-5), 35.4 (C-14), and 25.0 (C-15); FABMS m/z 561 ($\text{M}+\text{H}$)⁺; HRFABMS m/z 561.2050 ($\text{M}+\text{H}$)⁺, calcd for $\text{C}_{27}\text{H}_{33}\text{N}_2\text{O}_{11}$, 561.2084.

Compound (4): A colorless amorphous solid; IR (KBr) ν_{max} 3428 and 1644 cm^{-1} ; UV (MeOH) λ_{max} 217 (ϵ 23000), 259 (sh), 369 (10000), and 387 (9300) nm; ^1H NMR (CD_3OD): δ 7.62 (1H, d, $J = 8.0$ Hz, H-9), 7.43 (1H, d, $J = 8.2$ Hz, H-12), 7.27 (1H, dd, $J = 8.2$ and 7.8 Hz, H-11), 7.12 (1H, dd, $J = 8.0$ and 7.8 Hz, H-10), 6.68 (1H, s, H-14), 5.69 (1H, s, H-17), 5.56 (1H, d, $J = 7.4$ Hz, H-21), 5.55 (1H, dt, $J = 17.7$ and 9.7 Hz, H-19), 5.50 (1H, br d, $J = 17.7$ Hz, H-18a), 5.48 (1H, br d, $J = 9.7$ Hz, H-18b), 4.85 (1H, d, $J = 7.9$ Hz, H-1'), 4.53 (1H, m, H-5a), 4.36 (1H, m, H-5b), 3.92 (1H, br d, $J = 11.8$ Hz, H-6'a), 3.69 (1H, dd, $J = 11.8$ and 5.3 Hz, H-6'b), 3.65 (1H, s, MeO-17), 3.46 (1H, m, H-20), 3.46 (1H, m, H-3'), 3.35 (1H, m, H-4'), 3.35 (1H, m, H-5'), 3.27 (1H, m, H-2'), and 3.16 (2H, m, H-6); ^{13}C

NMR (CD₃OD): δ 162.8 (C-22), 149.8 (C-15), 141.2 (C-13), 140.4 (C-3), 135.9 (C-19), 129.2 (C-2), 127.6 (C-8), 126.3 (C-11), 122.6 (C-18), 122.0 (C-16), 121.7 (C-9), 121.2 (C-10), 116.5 (C-7), 113.6 (C-12), 102.6 (C-14), 100.3 (C-1'), 98.3 (C-17), 94.8 (C-21), 79.3 (C-3'), 79.0 (C-5'), 75.6 (C-2'), 72.7 (C-4'), 63.5 (C-6'), 57.0 (MeO-17), 50.1 (C-20), 42.8 (C-5), and 21.2 (C-6); FABMS m/z 549 (M+Na)⁺; HRFABMS m/z 549.1868 (M+Na)⁺, calcd for C₂₇H₃₀N₂O₉Na, 549.1849.

Compound (5): A colorless amorphous solid; IR (KBr) ν_{\max} 3436, 1643, and 1068 cm⁻¹; UV (MeOH) λ_{\max} 218 (ϵ 30000) and 261 (sh) nm; ¹H NMR (CD₃OD): δ 7.57 (1H, d, J = 8.1 Hz, H-9), 7.41 (1H, d, J = 1.9 Hz, H-17), 7.39 (1H, d, J = 7.4 Hz, H-12), 7.16 (1H, dd, J = 7.4 and 7.2 Hz, H-11), 7.09 (1H, dd, J = 8.1 and 7.2 Hz, H-10), 5.70 (1H, td, J = 10.0 and 6.9 Hz, H-19), 5.45 (1H, d, J = 1.9 Hz, H-21), 5.37 (2H, m, H-18), 5.35 (1H, m, H-5a), 5.02 (1H, br d, J = 5.6 Hz, H-3), 4.67 (1H, br s, H-6), 4.60 (1H, d, J = 8.1 Hz, H-1'), 3.96 (1H, dd, J = 11.8 and 2.5 Hz, H-6'a), 3.73 (1H, dd, J = 11.8 and 6.2 Hz, H-6'b), 3.57 (3H, s, MeO-6), 3.34 (1H, m, H-5'), 3.29 (1H, m, H-4'), 3.22 (1H, m, H-3'), 3.03 (1H, m, H-2'), 3.02 (1H, m, H-5b), 2.95 (1H, m, H-15), 2.71 (1H, ddd, J = 10.0, 6.9, and 1.9 Hz, H-20), 2.55 (1H, ddd, J = 13.7, 4.4, and 1.3 Hz, H-14a), and 2.08 (1H, td, J = 13.7 and 5.6 Hz, H-14b); ¹³C NMR (CD₃OD): δ 167.8 (C-22), 149.6 (C-17), 138.6 (C-13), 137.9 (C-2), 135.1 (C-19), 129.1 (C-8), 123.7 (C-11), 121.6 (C-10), 121.3 (C-18), 119.8 (C-9), 113.3 (C-12), 112.0 (C-7), 110.8 (C-16), 100.7 (C-1'), 98.3 (C-21), 79.1 (C-5'), 78.9 (C-3'), 78.3 (C-4'), 74.6 (C-6), 72.3 (C-2'), 63.5 (C-6'), 57.5 (MeO-6), 55.7 (C-3), 46.7 (C-5), 45.5 (C-20), 28.0 (C-14), and 25.8 (C-15); FABMS m/z 529 (M+H)⁺; HRFABMS m/z 529.2183 (M+H)⁺, calcd for C₂₇H₃₃N₂O₉, 529.2186.

Compound (6): A colorless amorphous solid; IR (KBr) ν_{\max} 3434, 1657, and 1051 cm⁻¹; UV (MeOH) λ_{\max} 223 (ϵ 22000) and 251 (sh) nm; ¹H NMR (CD₃OD): δ 7.66 (1H, d, J = 8.1 Hz, H-12), 7.52 (1H, d, J = 1.3 Hz, H-17), 7.51 (1H, dd, J = 8.1 and 7.5 Hz, H-11), 7.49 (1H, d, J = 7.5 Hz, H-9), 7.41 (1H, td, J = 7.5 and 1.3 Hz, H-10), 5.65 (1H, dt, J = 17.0 and 10.0 Hz, H-19), 5.57 (1H, d, J = 1.9 Hz, H-21), 5.44 (1H, dd, J = 17.0 and 1.9 Hz, H-18a), 5.35 (1H, dd, J = 10.0 and 1.9 Hz, H-18b), 4.74 (1H, d, J = 7.5 Hz, H-1'), 4.61 (1H, ddd, J = 13.1, 3.7, and 1.9 Hz, H-5a), 3.92 (1H, m, H-6'a), 3.71 (1H, m, H-6'b), 3.67 (1H, m, H-5b), 3.40 (1H, m, H-3'), 3.40 (3H, s, MeO-3), 3.37 (1H, m, H-5'), 3.32 (1H, m, H-4'), 3.26 (1H, m, H-15), 3.21 (1H, m, H-2'), 3.03 (3H, s, MeO-7), 2.81 (1H, ddd, J = 10.0, 5.6, and 1.9 Hz, H-20), 2.74 (1H, dd, J = 15.0 and 4.4 Hz, H-14a), 2.65 (1H, dt, J = 13.1 and 1.9 Hz, H-6a), 2.08 (1H, dd, J = 15.0 and 14.3 Hz, H-14b), and 1.43 (1H, td, J = 13.1 and 3.7 Hz, H-6b); ¹³C NMR (CD₃OD): δ 180.7 (C-2), 169.3 (C-8), 167.7 (C-22), 154.3 (C-13), 151.2 (C-17), 134.7 (C-19), 132.0 (C-11), 129.4 (C-10), 125.0 (C-9), 123.8 (C-12), 121.7 (C-18), 109.3 (C-16), 101.0 (C-1'), 98.9 (C-21), 90.4 (C-3), 88.9 (C-7), 78.9 (C-3'), 79.2 (C-5'), 75.5 (C-2'), 72.3 (C-4'), 63.5 (C-6'), 55.0 (MeO-7), 53.2 (MeO-3), 44.9 (C-20), 38.9 (C-6), 35.8 (C-5), 31.1 (C-14), and 24.1 (C-15); FABMS m/z 559 (M+H)⁺; HRFABMS m/z 559.2260 (M+H)⁺, calcd for C₂₈H₃₅N₂O₁₀, 559.2292.

ACKNOWLEDGMENTS

This work was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

REFERENCES AND NOTES

1. J. S. Bindra, 'Alkaloids', Vol. 14, ed. by H. L. Holmes, Academic Press, Inc., New York, 1973, pp. 83-121.
2. D. Ponglux, S. Wongseripipatana, N. Aimi, M. Nishimura, M. Ishikawa, H. Sada, J. Haginiwa, and S. Sakai, *Chem. Pharm. Bull.*, 1990, **38**, 573.
3. N. Aimi, T. Shimizu, H. Sada, H. Takayama, S. Sakai, S. Wongseripipatana, and D. I. Ponglux, *J. Chem. Soc., Perkin Trans. 1*, 1997, 187.
4. N. Aimi, T. Shito, K. Fukushima, Y. Itai, C. Aoyama, K. Kunisawa, S.-I. Sakai, J. Haginiwa, and K. Yamasaki, *Chem. Pharm. Bull.*, 1982, **30**, 4046.
5. The absolute configuration at C-7 of 7-hydroxyoxindole alkaloids has been elucidated by comparison of the CD spectra with those of known 7-hydroxyoxindole compounds. H. Takayama, T. Shimizu, H. Sada, Y. Harada, M. Kitajima, and N. Aimi, *Tetrahedron*, 1999, **55**, 6841; R. B. Labroo and L. A. Cohen, *J. Org. Chem.*, 1990, **55**, 4901.